Claim Amendments

1. (Currently Amended) Compounds having the structure of Formula I



Formula I

and their pharmaceutically acceptable salts, pharmaceutically acceptable ~~solvates, esters,~~ enantiomers, diastereomers, or N-oxides, ~~polymorphs, or metabolites~~,wherein Ar represents an aryl or a heteroaryl ring having 1-2 hetero atoms selected from the group consisting of oxygen, ~~sulphur~~ sulfur and nitrogen atoms, the aryl or heteroaryl rings may be unsubtituted or substituted by one to three substituents independently selected from lower alkyl (C_1-C_4), lower perhaloalkyl (C_1-C_4), cyano, hydroxy, nitro, halogen (e.g. F, Cl, Br, I), lower alkoxy (C_1-C_4), lower perhaloalkoxy (C_1-C_4), unsubstituted amino, N-lower alkylamino (C_1-C_4) or N-lower alkylamino carbonyl (C_1-C_4);

R_1 represents a hydrogen, hydroxy, hydroxymethyl, amino, alkoxy, carbamoyl or halogen (e.g. fluorine, chlorine, bromine and iodine);

R_2 represents hydrogen, alkyl, C_3-C_7 cycloalkyl ring, a C_3-C_7 cycloalkenyl ring, an aryl or a heteroaryl ring having 1-2 hetero atoms selected from the group consisting of oxygen, ~~sulphur~~ sulfur and nitrogen atoms, the aryl or a heteroaryl ring may be unsubstituted or substituted by one to three substituents independently selected from lower alkyl (C_1-C_4), cyano, hydroxy, nitro, lower alkoxycarbonyl, halogen, lower alkoxy (C_1-C_4), lower perhaloalkoxy (C_1-C_4), unsubstituted amino, N-lower alkylamino (C_1-C_4), N-lower alkyl amino carbonyl (C_1-C_4);

W represents $(CH_2)_p$, where p represents 0 to 1;

X represents an oxygen, ~~sulphur~~ sulfur, -NR or no atom, wherein R represents H or alkyl;

Y represents $(CH_2)q$ wherein q represents 0 to 1;

R_3, R_5 and R_6 are independently selected from H, lower alkyl, COOH, $CONH_2$, NH_2, CH_2NH_2; and

R_4 represents hydrogen, C_1-C_{15} saturated or unsaturated aliphatic hydrocarbon (straight chain or branched) in which any 1 to 6 hydrogen atoms may be substituted with the group independently selected from halogen, arylalkyl, arylakenyl, heteroarylalkyl or heteroarylalkenyl, having 1-2 hetero atoms selected from the group consisting of nitrogen, oxygen and ~~sulphur~~ sulfur atoms with an option that any 1 to 3 hydrogen atoms on the ring in said arylalkyl, arylalkenyl, heteroarylalkyl, heteroarylalkenyl group may be substituted with lower alkyl (C_1-C_4), lower perhaloalkyl (C_1-C_4), cyano, hydroxy, nitro, lower alkoxycarbonyl, halogen, lower alkoxy (C_1-C_4), lower perhalo alkoxy (C_1-C_4), unsubstituted amino, N-lower alkylamino (C_1-C_4), or N-lower alkylamino carbonyl (C_1-C_4).

2. (Currently Amended) A compound selected from the group consisting of (1α, 5α)-[3-benzyl-3-azabicyclo[3.1.0]-hex-1-(methyl)-yl]-2-hydroxy-2,2-diphenylcarboxylic ester (Compound No.1);

(1α, 5α)-[3-benzyl-3-azabicyclo[3.1.0]-hex-1-(methyl)-yl]-2-hydroxy-2-cyclohex yl-2-phenylcarboxlic ester (Compound No.2);

(1α, 5α)-[3-benzyl-3-azabicyclo[3.1.0]-hex-1-(methyl)-yl]-2-hydroxy-2-cyclopentyl-2-phenylcarboxylic ester (Compound No.3);

(1α, 5α)-[3-benzyl-3-azabicyclo[3.1.0]-hex-1-yl]-2-hydroxymethyl-2-phenylacitamide (Compound No.4);

(1α, 5α)-[3-benzyl-3-azabicyclo [3.1.0]-hex-1-yl]-2-hydroxy-2,2-diphenylacetamide (Compound No.5);

(1α, 5α)-[3-(2-methyl-2-pentenyl)-3-azabicyclo[3.1.0]-hex-1-(methyl)-yl]-2-hydroxy-2-cyclohexyl-2-phenylcarboxylic ester (Compound No.6); and

(1α, 5α)-[3-(3,4-methylenedioxyphen)ethyl-3-azabicyclo[3.1.0]-hex-1-(methyl)-yl]-2-hydroxy-2-cyclohexyl-2-phenylcarboxylic ester (Compound No.7).

3. (Original) A pharmaceutical composition comprising a therapeutically effective amount of a compound as defined in claim 1 or 2 optionally together with pharmaceutically acceptable carriers, excipients or diluents.

4.-17. (Previously cancelled)